Showing results (1671-1680 of 2,570) with videos related to

Sort By:
Pageof 257
Journal of Natural Products|October 30, 2013
Santacruzamate A, a potent and selective histone deacetylase inhibitor from the Panamanian marine cyanobacterium cf. Symploca spChristopher M Pavlik, Christina Y B Wong, Sophia Ononye, et al.
JAMA Network Open|January 2, 2025
Double CHEK2 Pathogenic and Low-Risk Variants and Associated Cancer PhenotypesBrittany L Bychkovsky, Nihat B Agaoglu, Carolyn Horton, et al.
JMIR Formative Research|August 23, 2023
A Nurse-Led Care Delivery App and Telehealth System for Patients Requiring Wound Care: Mixed Methods Implementation and Evaluation StudyCati G Brown-Johnson, Anna Sophia Lessios, Samuel Thomas, et al.
Health Behavior and Policy Review|October 3, 2025
Helping Everyone Achieve a LifeTime of Health - Future Addiction Scientist Training Program OutcomesAsfand B Moosa, Christina M Segura, Ammar D Siddiqi, et al.
Current Treatment Options in Rheumatology|December 7, 2020
Rheumatoid arthritis-associated interstitial lung disease: Current update on prevalence, risk factors, and pharmacologic treatmentSicong Huang, Vanessa L Kronzer, Paul F Dellaripa, et al.
Clinical Biochemistry|January 9, 2023
Targeting repetitive laboratory testing with electronic health records-embedded predictive decision support: A pre-implementation studyNaveed Rabbani, Stephen P Ma, Ron C Li, et al.
Environmental Research|March 8, 2022
Characterization of fetal exposure to multiple metals among an urban population: A case study of New York CityBrian Pavilonis, Andrew Maroko, Bo Cai, et al.
The Journal of Thoracic and Cardiovascular Surgery|August 12, 2008
Quality improvement program decreases mortality after cardiac surgerySotiris C Stamou, Sara L Camp, Robert M Stiegel, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 6, 2013
AMPKα2 exerts its anti-inflammatory effects through PARP-1 and Bcl-6Brendan Gongol, Traci Marin, I-Chen Peng, et al.
Clinical Colorectal Cancer|July 2, 2013
Treatment rationale and study design for a randomized, double-blind, placebo-controlled phase II study evaluating onartuzumab (MetMAb) in combination with bevacizumab plus mFOLFOX-6 in patients with previously untreated metastatic colorectal cancerJohanna C Bendell, Thomas J Ervin, David Gallinson, et al.
Pageof 257